Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy T Batchelor

Showing results (201-210 of 268) with videos related to

Pageof 27
Sort By:
Neuro-Oncology|October 6, 2021
Body CT and PET/CT detection of extracranial lymphoma in patients with newly diagnosed central nervous system lymphomaChong Hyun Suh, Ho Sung Kim, Sung Soo Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2013
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastomaTracy T Batchelor, Paul Mulholland, Bart Neyns, et al.
Radiology|November 9, 2021
Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent GlioblastomaMohamed E El-Abtah, Michael R Wenke, Pratik Talati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2014
Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomasHiroaki Wakimoto, Shota Tanaka, William T Curry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
It is time to include patients with brain tumors in phase I trials in oncologyPatrick Y Wen, David Schiff, Timothy F Cloughesy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomaTracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, et al.
Neuro-Oncology Advances|June 16, 2021
MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastomaPratik Talati, Mohamed El-Abtah, Daniel Kim, et al.
Neuro-Oncology|January 10, 2015
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic gliomaEudocia Q Lee, David A Reardon, David Schiff, et al.
Blood|February 28, 2019
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cellsPhilipp Karschnia, Justin T Jordan, Deborah A Forst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphomaLauren E Abrey, Tracy T Batchelor, Andrés J M Ferreri, et al.
Pageof 27

Showing results (201-210 of 268) with videos related to

Sort By:
Pageof 27
Neuro-Oncology|October 6, 2021
Body CT and PET/CT detection of extracranial lymphoma in patients with newly diagnosed central nervous system lymphomaChong Hyun Suh, Ho Sung Kim, Sung Soo Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2013
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastomaTracy T Batchelor, Paul Mulholland, Bart Neyns, et al.
Radiology|November 9, 2021
Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent GlioblastomaMohamed E El-Abtah, Michael R Wenke, Pratik Talati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2014
Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomasHiroaki Wakimoto, Shota Tanaka, William T Curry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
It is time to include patients with brain tumors in phase I trials in oncologyPatrick Y Wen, David Schiff, Timothy F Cloughesy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomaTracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, et al.
Neuro-Oncology Advances|June 16, 2021
MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastomaPratik Talati, Mohamed El-Abtah, Daniel Kim, et al.
Neuro-Oncology|January 10, 2015
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic gliomaEudocia Q Lee, David A Reardon, David Schiff, et al.
Blood|February 28, 2019
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cellsPhilipp Karschnia, Justin T Jordan, Deborah A Forst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphomaLauren E Abrey, Tracy T Batchelor, Andrés J M Ferreri, et al.
Pageof 27